- **Wegovy (Semaglutide):**

 


- Medication for weight management in adults with obesity or overweight and at least one weight-related condition.
- Belongs to the GLP-1 receptor agonists class.
- Mimics effects of natural hormone GLP-1 to reduce appetite and increase fullness.
- Administered via weekly subcutaneous injection.
- Used alongside reduced-calorie diet and increased physical activity.
- Clinically shown to lead to significant weight loss.
- Potential side effects include nausea, vomiting, and hypoglycemia.

  • Mechanism: Mimics natural hormone GLP-1 to regulate appetite and food intake.
    • Administration: Weekly subcutaneous injections.
    • Complementary: Used with reduced-calorie diet and increased physical activity.
    • Effectiveness: Clinically proven to induce significant weight loss.
    • Considerations: Discuss potential side effects and benefits with healthcare provider.
    • Side Effects: May include nausea, vomiting, and hypoglycemia.
    • Health Conditions: Suitable for adults with obesity or overweight and at least one weight-related condition.
    • Impact: Offers a promising option for weight management in individuals struggling with other interventions.